Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells. 1989

Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
Cancer Center, Kyushu University Hospital, Fukuoka, Japan.

The metabolism of 1-beta-D-arabinofuranosylcytosine (ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) was studied in Hela cells. After the cells were exposed to ara-C at a concentration of 20 micrograms/ml or BH-AC at 46.5 micrograms/ml for 1, 3, 6, 12 or 24 hr, the level of ara-C was determined using the radioimmunoassay method, and the level of BH-AC and 1-beta-D-arabinofuranosyluracil (ara-U), using high-performance liquid chromatography. In the ara-C-treated cells, the intracellular ara-C increased to 1.26 micrograms/g cells after exposure for 6 hr, and ara-C was rapidly changed to ara-U in the cells and in the medium. In the BH-AC-treated cells, the intracellular BH-AC increased after exposure for 24 hr and BH-AC was gradually converted to ara-C in the cells: the intracellular level of ara-C was only 15% of that of BH-AC after exposure for 24 hr. BH-AC level in the medium persisted for 24 hr, at the initial concentration. Our findings show that BH-AC is stable compared to ara-C and gradually converts to ara-C. This conversion is presumably a critical step in the antineoplastic effect of BH-AC.

UI MeSH Term Description Entries
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001086 Arabinofuranosyluracil A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE. Ara-U,Arabinosyluracil,Arauridine,Sponguridine,Uracil Arabinofuranoside,Uracil Arabinoside,1-beta-D-Arabinofuranosyl Uracil,NSC 68928,1 beta D Arabinofuranosyl Uracil,Ara U,Arabinofuranoside, Uracil,Arabinoside, Uracil,Uracil, 1-beta-D-Arabinofuranosyl

Related Publications

Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
January 1989, Advances in experimental medicine and biology,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
January 1988, Medical oncology and tumor pharmacotherapy,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
June 1983, Gan,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
January 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
January 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
October 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
September 1987, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
June 1981, Cancer research,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
August 1977, Cancer research,
Y Maehara, and T Kusumoto, and Y Sakaguchi, and H Kusumoto, and H Anai, and K Sugimachi
July 1983, Cancer research,
Copied contents to your clipboard!